Xevudy 500 mg concentrate for solution for infusion
Sponsors
National Institute For Infectious Diseases Lazzaro Spallanzani, Stichting Amsterdam UMC
Conditions
Covid-19 infectionSARS-CoV-2 infection
Phase 4
Temporal kinetics of antibody and cellular response markers and relative impact of
revaccination in patients recovered from COVID-19 after treatment with monoclonal
antibodies
Not yet recruitingCTIS2024-514071-17-00
Target: 150Updated: 2025-01-14
TURN-COVID Biobank: The Dutch cohort study tor the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2
CompletedCTIS2024-515263-60-00
Start: 2024-11-22End: 2025-05-25Target: 400Updated: 2024-11-22